Morgan Stanley Theseus Pharmaceuticals, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.12 - $4.18 $110,708 - $218,283	52,221 Added 135.39%	90,791 $367,000
Q3 2023 Nov 15, 2023	SELL	$2.66 - $10.04 $3,742 - $14,126	-1,407 Reduced 3.52%	38,570 $103,000
Q2 2023 Aug 14, 2023	SELL	$7.28 - $11.82 $13,904 - $22,576	-1,910 Reduced 4.56%	39,977 $372,000
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $158,430 - $427,246	30,409 Added 264.93%	41,887 $371,000
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $12,761 - $22,747	2,721 Added 31.07%	11,478 $57,000

Q3 2022 Nov 14, 2022	SELL	$5.7 - $8.68 $22,093 - $33,643	-3,876 Reduced 30.68%	8,757 $51,000
Q2 2022 Oct 27, 2022	BUY	$5.04 - $14.05 $15,044 - $41,939	2,985 Added 30.94%	12,633 $70,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $15,044 - $41,939	2,985 Added 30.94%	12,633 $70,000
Q1 2022 Oct 27, 2022	SELL	$8.75 - $14.51 $26,118 - $43,312	-2,985 Reduced 23.63%	9,648 $111,000
Q1 2022 May 13, 2022	SELL	$8.75 - $14.51 $271 - $449	-31 Reduced 0.32%	9,648 $111,000
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $86,917 - $194,451	9,679 New	9,679 $123,000

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.